Stephens initiated coverage of Candel Therapeutics (CADL) with an Overweight rating and $15 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Positive Buy Rating for Candel Therapeutics Driven by Promising Phase 3 Results of CAN-2409 and Strong Regulatory Prospects
- Candel Therapeutics initiated with an Outperform at LifeSci Capital
- Candel Therapeutics appoints Pulendran to Candel’s RAB
- Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty
- Candel Therapeutics Secures $130M Loan for Trials